These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38232909)

  • 41. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
    Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour T; Kern S; Lew C; Zimmerman N; Murage M
    Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
    Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
    JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
    Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
    Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switching biologics in children with psoriasis: Results from the BiPe cohort.
    Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
    Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
    Takeuchi T; Nishikawa K; Yamada F; Morita A; Ohtsuki M; Suzuki Y; Watanabe M; Yamanaka H; Hibi T
    Drug Saf; 2023 Oct; 46(10):991-1005. PubMed ID: 37700154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis.
    Siegel SAR; Winthrop KL
    Curr Rheumatol Rep; 2019 Jun; 21(7):36. PubMed ID: 31172303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.
    Vender RB; Lynde CW
    J Cutan Med Surg; 2022; 26(3):267-273. PubMed ID: 35134313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
    Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
    J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.
    Taipale H; Schneider-Thoma J; Pinzón-Espinosa J; Radua J; Efthimiou O; Vinkers CH; Mittendorfer-Rutz E; Cardoner N; Pintor L; Tanskanen A; Tomlinson A; Fusar-Poli P; Cipriani A; Vieta E; Leucht S; Tiihonen J; Luykx JJ
    JAMA Psychiatry; 2022 Mar; 79(3):210-218. PubMed ID: 35080618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence.
    Yu CL; Yang CH; Chi CC
    BioDrugs; 2020 Oct; 34(5):669-679. PubMed ID: 32946076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Using real-world evidence data and digital monitoring to analyze the hepatotoxic profiles of biologics across more than two million patients.
    Banerjee P; Preissner S; Preissner R
    Sci Rep; 2023 Jul; 13(1):10878. PubMed ID: 37407661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
    Pina Vegas L; Penso L; Claudepierre P; Sbidian E
    JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.
    Ighani A; Yu AM; Sandhu VK; Barankin B; Manolson MF
    J Cutan Med Surg; 2019; 23(2):148-156. PubMed ID: 30801221
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse effects of biologics: a network meta-analysis and Cochrane overview.
    Singh JA; Wells GA; Christensen R; Tanjong Ghogomu E; Maxwell L; Macdonald JK; Filippini G; Skoetz N; Francis D; Lopes LC; Guyatt GH; Schmitt J; La Mantia L; Weberschock T; Roos JF; Siebert H; Hershan S; Lunn MP; Tugwell P; Buchbinder R
    Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD008794. PubMed ID: 21328309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.
    Carretero Hernández G; Ferrándiz C; Rivera Díaz R; Daudén Tello E; de la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Belinchón Romero I; López-Estebaranz JL; Alsina Gibert M; Sánchez-Carazo JL; Ferrán Farrés M; González Quesada A; Carrascosa Carrillo JM; Llamas-Velasco M; Mendiola Fernández MV; Ruiz Genao D; Muñoz Santos C; García-Doval I; Descalzo MA;
    Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):617-623. PubMed ID: 29887167
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biologics for pediatric psoriasis: A systematic review and meta-analysis.
    Sun HY; Phan K; Paller AS; Sebaratnam DF
    Pediatr Dermatol; 2022 Jan; 39(1):42-48. PubMed ID: 34888919
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
    Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
    Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.